Daxor (NASDAQ: DXR) — Perfil da empresa, notícias e dados financeiros
Daxor specializes in medical instrumentation for blood volume analysis benefiting heart failure patient care.
Daxor
Daxor (NASDAQ:DXR) specializes in medical instrumentation and biotechnology, focusing on innovative blood volume analysis. This unique approach provides critical information that benefits patient care in heart failure, critical care, and surgery, alongside supporting medical research. Daxor aims to revolutionize how doctors diagnose and treat heart and lung diseases by offering precise, personalized patient insights. The company's flagship product, the BVA-100 blood volume analyzer, stands at the forefront of their technology, enabling accurate measurement of blood volume and composition. Daxor's objective is to improve outcomes and reduce healthcare costs through the adoption of their blood volume analysis technology in clinical practices worldwide.
Resumo
Operações
Produtos e/ou serviços de Daxor
- BVA-100 Blood Volume Analyzer, a diagnostic device providing precise blood volume status for improved patient care.
- Blood volume analysis services, aiding in diagnosis and treatment of heart failure and critical care.
- R&D for advancements in blood volume measurement technology, enhancing diagnostic precision and patient outcomes.
- Educational programs for healthcare professionals, focusing on the importance of blood volume measurement in clinical decisions.
- Partnerships with healthcare institutions for research and development of novel diagnostic approaches.
- Development of next-gen technologies for non-invasive blood volume measurement, aiming at broader clinical applications.
equipe executiva do Daxor
- Michael Richard FeldschuhChairman, President & CEO
- Robert J. MichelCFO, Chief Compliance Officer & Corporate Secretary
- Jonathan Adam FeldschuhChief Scientific Officer & Director
- John Lynn JefferiesChief Medical Officer
- Linda CooperVice President of Development & Operations
- Kathryn A. KornafelSenior VP of Marketing & Commercial Development
- Annette PlishkaSenior Vice President of Commercialization
Histórico de dividendos
Dividendos por ação pagos pela Daxor , por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2018 | — | — | — | $0.0300 |
| FY2017 | — | — | — | $0.0300 |
| FY2016 | — | — | — | $0.0300 |
| FY2015 | — | — | — | $0.0400 |
| FY2014 | — | — | — | $0.0300 |
Principais indicadores financeiros
Resultados divulgados pela Daxor , em USD.
- Cap. de mercado
- 52,4 mi
- Receita (TTM)
- 31,4 mil
- P/L
- 8.2
- LPA (diluído, TTM)
- 1.1
- Dividend yield
- —
- Margem de lucro
- 19861.4%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 503,4 mil | 9,2 mi | 9,2 mi | |
| 2,1 mi | 621,4 mil | 536,3 mil | |
| 34,6 mi | 329,7 mil | 280,6 mil | |
| 6,3 mi | 5,3 mi | 5,2 mi |